TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05887141

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Double Standards
Description: We created a VR intervention based on the Cognitive Behavioral Therapy (CBT) technique 'double standards'. In the intervention the participants have to respond to a virtual character they imagine as their friend, who expresses similar self-criticism as they struggle with themselves. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with the virtual friend (second person perspective).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double Standards
Description: We created a VR intervention based on the Cognitive Behavioral Therapy (CBT) technique 'double standards'. In the intervention the participants have to respond to a virtual character they imagine as their friend, who expresses similar self-criticism as they struggle with themselves. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with the virtual friend (second person perspective).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-criticism avatar
Description: We created a VR intervention called 'Self-criticism avatar' that has common ground with two-chair dialogue. Participants have to assertively respond to their inner critic who criticizes them using their own self-critical thoughts. After responding assertively (for example: 'Go away, I don't need you', 'Good is good enough'), the virtual character becomes weaker until they give up. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with a bystander (third person perspective).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-criticism avatar
Description: We created a VR intervention called 'Self-criticism avatar' that has common ground with two-chair dialogue. Participants have to assertively respond to their inner critic who criticizes them using their own self-critical thoughts. After responding assertively (for example: 'Go away, I don't need you', 'Good is good enough'), the virtual character becomes weaker until they give up. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with a bystander (third person perspective).
Study: NCT06428877

Intervention type: OTHER
Intervention: analyzed on the post-operative scanner
Description: analyzed on the post-operative scanner
Study: NCT04933799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-06650833
Description: PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will match the study drug in dose, formulation, route and frequency.
Study: NCT05018897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: To Share or Not to Share
Description: Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met. Six one-hour virtual sessions conducted weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support
Description: Peer-led support group for mood disorders. Six one-hour virtual sessions conducted weekly.
Study: NCT06124976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-02
Description: ST-02 drug instillation into the upper urinary tract (renal pelvis)
Study: NCT05333822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bashan
Description: a vegetable plant based compound drink add after three meals for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: water as placebo
Study: NCT05579665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma
Description: Research participants own blood will be used to prepare the platelet rich plasma injectate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome
Description: Conditioned Medium UC-MSCs Secretome which will be injected into the affected knee using ultrasound guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Hyaluronic Acid
Description: low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
Study: NCT05296447

Intervention type: OTHER
Intervention: No Intervention
Description: All subjects that previously received RGX-314 in a parent study
Study: NCT04795583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 25 mg capsules

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Point of Care testing device for C-reactive protein
Description: Determination of C-reactive protein blood levels by point of care testing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of Care testing device for C-reactive protein
Description: Determination of C-reactive protein blood levels by point of care testing device
Study: NCT05354310

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VOILA
Description: Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VOILA
Description: Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VOILA
Description: Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.
Study: NCT05828563

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample test
Description: Blood sample will be taken to determine immunological indices

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample test
Description: Blood sample will be taken to determine immunological indices
Study: NCT05559983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSP:rTTHc Cholera Conjugate Vaccine Cohort A
Description: OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A
Description: OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cohort A
Description: Sterile 0.9% sodium chloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSP:rTTHc Cholera Conjugate Vaccine Cohort B
Description: OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort B
Description: OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
Study: NCT06137209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Study Group A: Blis Q24 Serum at higher dose
Description: Active Comparator: Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Study Group B: Blis Q24 Serum at lower dose
Description: Active Comparator: Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)
Study: NCT06204120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392 Injection
Description: PCA administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392 Injection
Description: PCA administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392 Injection
Description: PCA administration
Study: NCT05559983

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cohort B
Description: Sterile 0.9% sodium chloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSP:rTTHc Cholera Conjugate Vaccine Cohort C
Description: OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort C
Description: OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cohort C
Description: Sterile 0.9% sodium chloride
Study: NCT05024409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper Extremity Orthotic
Description: 3D printed orthotic which uses elbow motion to facilitate finger extension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: 6 weekly sessions of occupational therapy, without use of an assistive orthotic device
Study: NCT06074653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Bent Leg Raise technique
Description: Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given.Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Contract Relax technique
Description: Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given. Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
Study: NCT05757778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory Nerve Coaptation
Description: Nerve reconstruction will employ an off-the-shelf nerve graft coapted to the donor anterior intercostal nerve branch laterally and medially at the underside of the nipple. The anterior intercostal nerve branch and nerve graft coaptation will be performed in a standard fashion with a 1 mm gap between the ends of the graft and the donor nerve. Medially, the nerve graft will be inset into the underside of the preserved nipple-areola complex using 8-0 or 9-0 epineural stitches from the nerve allograft. All nerve coaptations will be performed under loupe magnification as is standardly performed.
Study: NCT04469062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab SC
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Administered SC
Study: NCT05585177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: 3 months of growth hormone treatment (2 units daily)
Study: NCT05191836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment
Description: The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment
Description: The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids
Description: The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times.
Study: NCT05060835

Intervention type: OTHER
Intervention: Virtual assistants offering medical recommendations to health care profesionals
Description: the project will interconnect, following a federated approach, large, distributed cancer imaging repositories, currently used for AI tools training and validation, with patient registries and EHRs of cancer-related data and supports exploitation of relevant unstructured data through novel Natural Language Processing (NLP) tools

Intervention type: OTHER
Intervention: Virtual assistants offering medical recommendations to health care profesionals
Description: the project will interconnect, following a federated approach, large, distributed cancer imaging repositories, currently used for AI tools training and validation, with patient registries and EHRs of cancer-related data and supports exploitation of relevant unstructured data through novel Natural Language Processing (NLP) tools
Study: NCT05997459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib,13.5mg ,QD,po, 2 weeks / 1 week;Q 3W
Study: NCT05043883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CathVision Cube® system
Description: Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.
Study: NCT05364645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Given PO
Study: NCT05092477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention for Breast Cancer Survivors with Diabetes
Description: All pilot participants will be required to have a SMB target to be included in this study. A SMB target will be chosen by the participant after reviewing their 18mo follow-up responses with the Care Coach. Participants may endorse a maladaptive belief or emotional response; however, this is not required to participate in this intervention. At each follow-up session, the Care Coach will review the participant's SMB goal and progress, address participant's challenges and suggest alternatives, and correct further misinformation on the disease(s). Additionally, the Care Coach will reinforce or introduce techniques that could help overcome barriers to reaching SMB goal and recommend participants to continue improving on the same goal or begin action planning towards a new SMB goal.~1. Just SMB concern~2. SMB + maladaptive belief + emotional response~3. SMB + maladaptive belief~4. SMB + emotional response

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in the control arm will receive a brochure to discuss healthy lifestyle behaviors to improve DM management. To control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes, participants also receive 4 calls to discuss study progress, thoughts and feelings about study/illness/behaviors, remind them about returning their pill bottles, and about scheduling for their upcoming 24mo follow-up study interview.
Study: NCT05267678

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention
Study: NCT05342519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: While rapamycin is not approved for the treatment of vitiligo, it has been found to be efficacious in stopping disease progression in animal models. Another recent study in humans showed that doses of 0.5cc daily of 0.001% of the topical formulation are able to achieve improvement in hypopigmented lesions of the skin at both the clinical and histological level. At this dose, improvement in cell function was observed regarding maintenance of proliferative potential and prevention of senescence, with avoidance of total inhibition of cell growth as has been seen at higher potencies used for immunosuppression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Rapamycin is an immunosuppressant that works by inhibiting the mammalian target of rapamycin (mTOR) leading to inhibition of the cell cycle and antibody production. It has also been shown to promote expansion of Treg populations. Although studies evaluating alternative dosing for vitiligo are limited, topical rapamycin has previously been used to treat angiofibromas related to Tuberous Sclerosis, vascular malformations such as port-wine stains, and inflammatory lesions such as plaque psoriasis. In a 2019 meta-analysis, 38 out of 40 reports included used topical formulations of 1% or lower potency rapamycin; the majority of publications were focused on the treatment of Tuberous Sclerosis, where the median concentration of mTOR inhibition was 0.1% dosed twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will be assigned to received topical placebo cream to the lesion not being treated with the active study drug.
Study: NCT06497790

Intervention type: DIAGNOSTIC_TEST
Intervention: BJH-SDS Screenint Test
Description: The test includes the assessment of a sufficient level of consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality)

Intervention type: DIAGNOSTIC_TEST
Intervention: BJH-SDS Screenint Test
Description: The test includes the assessment of a sufficient level of consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality)

Intervention type: DIAGNOSTIC_TEST
Intervention: BJH-SDS Screenint Test
Description: The test includes the assessment of a sufficient level of consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality)

Intervention type: DIAGNOSTIC_TEST
Intervention: Flexible Endoscopic Evaluation of Swallowing
Description: The FEES evaluates anatomical changes, functional disorders of the visible structures (e.g. recurrent paresis), saliva management, penetration and aspiration of food boluses in order to draw conclusions about the underlying pathomechanism of dysphagia. It is an established standard diagnostic procedure for stroke patients and, in addition to the diagnosis of dysphagia, also enables pathomechanism-guided therapy by speech therapists
Study: NCT06204120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392 Injection
Description: PCA administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PCA administration